Roy Howard Perlis MD
Director of the Center for Experimental Drugs and Diagnostics (CEDD) and Associate Director of the Psychiatric Genetics Program in Mood and Anxiety Disorders in the MGH Psychiatry Department Associate Professor of Psychiatry at Harvard Medical School and serves as a consultant to the American Psychiatric Association's bipolar treatment guidelines workshop
Join to View Full Profile
15 Parkman Street Wac 812Psychiatry Outpatient DepartmentBoston, MA 02114
Phone+1 617-724-5600
Fax+1 617-724-3028
Dr. Perlis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1997 - 2001- Mass General Brigham/Massachusetts General HospitalInternship, Internal Medicine, 1997 - 1998
Harvard Medical SchoolClass of 1997
Certifications & Licensure
MI State Medical License 2025 - 2028
MT State Medical License 2025 - 2027
WV State Medical License 2025 - 2027
WI State Medical License 2025 - 2027
TX State Medical License 2025 - 2027
TN State Medical License 2025 - 2027
NY State Medical License 2025 - 2027
American Board of Psychiatry and Neurology Psychiatry- Join now to see all
Clinical Trials
- Effectiveness of Pramipexole for Treatment-Resistant Depression Start of enrollment: 2003 Sep 01
- Simvastatin Augmentation of Lithium Treatment in Bipolar Depression Start of enrollment: 2012 Aug 01
- Adjunctive Isradipine for the Treatment of Bipolar Depression Start of enrollment: 2013 Feb 01
Publications & Presentations
PubMed
- Conspiratorial thinking in a 50-state survey of American adults.Roy H Perlis, Ata Uslu, Sergio A Barroilhet, Paul A Vohringer, Anudeepa K Ramachandiran
Journal of Affective Disorders. 2025-12-01 - Clinical decision support for pharmacologic management of treatment-resistant depression with augmented large language models.Roy H Perlis, Pilar F Verhaak, Joseph Goldberg, Cristina Cusin, Michael Ostacher
Journal of Mood and Anxiety Disorders. 2025-12-01 - Characterizing population-level changes in human behavior during the COVID-19 pandemic in the United States.Tamanna Urmi, Binod Pant, George Dewey, Alexi Quintana-Mathe, Iris Lang
Proceedings of the National Academy of Sciences of the United States of America. 2025-09-16
Journal Articles
- Psychiatry and COVID-19Roy Perlis, Donald Goff, JAMA
- Can Electronic Health Records Revive Central Nervous System Clinical Trials?Maurizio Fava, Roy H Perlis, Nature
- Temporal Trends and Characteristics of Reportable Health Data Breaches, 2010-2017Roy Perlis, MD, JAMA
Lectures
- Effect of Cytochrome CYP2C19 Metabolizing Activity on Antidepressant Response and Side Effects: Meta-Analysis of Data from Genome-Wide Association Studies162nd Annual Meeting, San Francisco, California, USA
- Discovery of a Highly Selective Glycogen Synthase Kinase‐3 Inhibitor (PF‐04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET NeuroimagingAmerican Psychiatric Association, 162nd Annual Meeting, San Francisco, California, USA
Authored Content
- The Time Has Come for Over-the-Counter AntidepressantsApril 2024
- Genome-Wide Association Study of Dimensional Psychopathology Using Electronic Health RecordsFebruary 2018
- High Throughput Phenotyping for Dimensional Psychopathology in Electronic Health RecordsFebruary 2018
Press Mentions
Platelet Transfusion in Preterm Infants, Pediatric Solid Organ Transplants, Measles Case Tracking, and MoreSeptember 19th, 2025- ESC Highlights, Reporting Guidelines for Target Trial Emulation Studies, LSD for Anxiety and MoreSeptember 5th, 2025
- Can 3 Questions Accurately Flag Depression? PHQ-3 Put to the TestJuly 30th, 2025
- Join now to see all
Grant Support
- Scalable Phenotyping to Assay Risk in Childhood after eXposures in Pregnancy: SPARC-XPMASSACHUSETTS GENERAL HOSPITAL2025–2029
- JASPer-MH: Jointly Assessed Scalable Phenotypes for Mental HealthMASSACHUSETTS GENERAL HOSPITAL2024–2029
- JASPer-MH: Jointly Assessed Scalable Phenotypes for Mental HealthMASSACHUSETTS GENERAL HOSPITAL2024–2029
- Characterization of schizophrenia liability genes in models of human microglial synaptic pruningMASSACHUSETTS GENERAL HOSPITAL2023–2028
- Depression, Isolation, and Social Connectivity Online (DISCO)MASSACHUSETTS GENERAL HOSPITAL2022–2025
- Cellular models of fetal neurodevelopment in maternal SARS-CoV-2 infectionMASSACHUSETTS GENERAL HOSPITAL2022–2025
- Data-driven subtyping in major depressive disorderMASSACHUSETTS GENERAL HOSPITAL2021–2025
- Patient-derived Models of Synaptic Pruning in SchizophreniaMASSACHUSETTS GENERAL HOSPITAL2019–2025
- In Vitro And In Vivo Study Of Simvastatin PLUS Lithium In Bipolar DepressionNational Institute Of Mental Health2012
- Building A Risk Stratification Model For Treatment Resistance In Major DepressiveNational Institute Of Mental Health2009–2011
- Pramipexole In Treatment-Resistant DepressionNational Institute Of Mental Health2003–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
